guest ::
| Home > Publications database > Molecular subtypes of intrahepatic cholangiocarcinoma. > print |
| 001 | 298945 | ||
| 005 | 20250827125447.0 | ||
| 024 | 7 | _ | |a 10.1016/j.molmed.2025.01.008 |2 doi |
| 024 | 7 | _ | |a pmid:39955217 |2 pmid |
| 024 | 7 | _ | |a 1471-4914 |2 ISSN |
| 024 | 7 | _ | |a 1471-499X |2 ISSN |
| 024 | 7 | _ | |a altmetric:174376024 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-00379 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a De Santis, Alessandro |0 P:(DE-He78)9a1cac3459b4368615b3d544b5682435 |b 0 |e First author |
| 245 | _ | _ | |a Molecular subtypes of intrahepatic cholangiocarcinoma. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1756292055_16148 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A430#LA:A430# / 2025 Aug;31(8):755-769 |
| 520 | _ | _ | |a Intrahepatic cholangiocarcinoma (iCCA) presents in two clinically distinct subtypes: large duct (LD-iCCA) and small duct (SD-iCCA). These subtypes exhibit significant molecular, genetic, and histopathological differences that impact patient prognosis and treatment responsiveness. This review advocates for a subtype-specific approach to iCCA research and clinical management, including tailored therapeutic strategies that consider distinct genetic profiles and tumor microenvironments. Current therapeutic approaches hold promise, yet efficacy varies by subtype. Additionally, subtype-specific molecular diagnostics, including DNA methylation-based classifiers and transcriptomic sequencing, have shown potential in refining iCCA subclassification, thereby guiding precision medicine efforts. This article outlines existing clinical trials, key research trajectories, and future directions for developing more effective subtype-adapted therapies for iCCA. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a clinical trial |2 Other |
| 650 | _ | 7 | |a intrahepatic cholangiocarcinoma |2 Other |
| 650 | _ | 7 | |a molecular targeted therapy |2 Other |
| 650 | _ | 7 | |a mutation |2 Other |
| 650 | _ | 7 | |a survival |2 Other |
| 650 | _ | 7 | |a translational research |2 Other |
| 700 | 1 | _ | |a Zhu, Lei |0 P:(DE-He78)0116f5652cc0dbf455e3aa3914740230 |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Tao, Jianxin |0 P:(DE-He78)27fb0d2bd2832c8c977e636025736942 |b 2 |u dkfz |
| 700 | 1 | _ | |a Reißfelder, Christoph |b 3 |
| 700 | 1 | _ | |a Schölch, Sebastian |0 P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e |b 4 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.molmed.2025.01.008 |g p. S1471491425000085 |0 PERI:(DE-600)2155736-6 |n 8 |p 755-769 |t Trends in molecular medicine |v 31 |y 2025 |x 1471-4914 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:298945 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)9a1cac3459b4368615b3d544b5682435 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)0116f5652cc0dbf455e3aa3914740230 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)27fb0d2bd2832c8c977e636025736942 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TRENDS MOL MED : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-01-06 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2025-01-06 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b TRENDS MOL MED : 2022 |d 2025-01-06 |
| 920 | 2 | _ | |0 I:(DE-He78)A430-20160331 |k A430 |l NWG-KKE Translationale Chirurgische Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A430-20160331 |k A430 |l NWG-KKE Translationale Chirurgische Onkologie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)A430-20160331 |k A430 |l NWG-KKE Translationale Chirurgische Onkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A430-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|